Which has preferable valuation and earnings, AMRN or PCRX?

Pacira BioSciences has higher revenue and earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Amarin $213.65M 1.19 -$38.80M -$0.99 N/A Pacira BioSciences $726.41M 1.99 $7.03M $0.35 103.74

Does the media favor AMRN or PCRX?

In the previous week, Pacira BioSciences had 49 more articles in the media than Amarin. MarketBeat recorded 53 mentions for Pacira BioSciences and 4 mentions for Amarin. Amarin's average media sentiment score of 1.10 beat Pacira BioSciences' score of 0.30 indicating that Amarin is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amarin 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pacira BioSciences 10 Very Positive mention(s) 13 Positive mention(s) 17 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer SPTX or AMRN?

In the previous week, Seaport Therapeutics had 7 more articles in the media than Amarin. MarketBeat recorded 11 mentions for Seaport Therapeutics and 4 mentions for Amarin. Amarin's average media sentiment score of 1.10 beat Seaport Therapeutics' score of 0.10 indicating that Amarin is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Seaport Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 3 Very Negative mention(s) Neutral Amarin 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ANRO or AMRN?

In the previous week, Amarin had 2 more articles in the media than Alto Neuroscience. MarketBeat recorded 4 mentions for Amarin and 2 mentions for Alto Neuroscience. Amarin's average media sentiment score of 1.10 beat Alto Neuroscience's score of 0.22 indicating that Amarin is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alto Neuroscience 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Amarin 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, AMRN or HELP?

Amarin has higher revenue and earnings than Cybin. Amarin is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Amarin $213.65M 1.19 -$38.80M -$0.99 N/A Cybin N/A N/A -$148M -$3.02 N/A

Is AMRN or HELP more profitable?

Cybin has a net margin of 0.00% compared to Amarin's net margin of -14.56%. Amarin's return on equity of -0.20% beat Cybin's return on equity. Company Net Margins Return on Equity Return on Assets Amarin -14.56% -0.20% -0.14% Cybin N/A -71.78% -64.81%

Does the media favor AMRN or HELP?

In the previous week, Cybin had 1 more articles in the media than Amarin. MarketBeat recorded 5 mentions for Cybin and 4 mentions for Amarin. Amarin's average media sentiment score of 1.10 beat Cybin's score of 0.87 indicating that Amarin is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amarin 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cybin 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Amarin (AMRN) Competitors

$12.03 +0.04 (+0.33%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$11.94 -0.09 (-0.78%)

As of 10/9/2026 07:30 PM Eastern

Compare

AMRN vs. PCRX, SPTX, ANRO, HELP, and TBPH

Should you buy Amarin stock or one of its competitors? Amarin's main competitors and comparable companies include Pacira BioSciences (PCRX), Seaport Therapeutics (SPTX), Alto Neuroscience (ANRO), Cybin (HELP), and Theravance Biopharma (TBPH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Amarin compare to Pacira BioSciences?

Amarin (NASDAQ:AMRN) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.

Pacira BioSciences has a net margin of 1.96% compared to Amarin's net margin of -14.56%. Pacira BioSciences' return on equity of 9.68% beat Amarin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amarin	-14.56%	-0.20%	-0.14%
Pacira BioSciences	1.96%	9.68%	5.30%

Amarin has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, Pacira BioSciences has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market.

Amarin presently has a consensus price target of $13.00, suggesting a potential upside of 8.06%. Pacira BioSciences has a consensus price target of $33.33, suggesting a potential downside of 8.20%. Given Amarin's higher probable upside, equities research analysts plainly believe Amarin is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00
Pacira BioSciences	1 Sell rating(s)	9 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Pacira BioSciences had 49 more articles in the media than Amarin. MarketBeat recorded 53 mentions for Pacira BioSciences and 4 mentions for Amarin. Amarin's average media sentiment score of 1.10 beat Pacira BioSciences' score of 0.30 indicating that Amarin is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amarin	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pacira BioSciences	10 Very Positive mention(s)	13 Positive mention(s)	17 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

22.3% of Amarin shares are owned by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are owned by institutional investors. 4.2% of Amarin shares are owned by insiders. Comparatively, 6.4% of Pacira BioSciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Pacira BioSciences has higher revenue and earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$213.65M	1.19	-$38.80M	-$0.99	N/A
Pacira BioSciences	$726.41M	1.99	$7.03M	$0.35	103.74

Summary

Pacira BioSciences beats Amarin on 12 of the 16 factors compared between the two stocks.

How does Amarin compare to Seaport Therapeutics?

Seaport Therapeutics (NASDAQ:SPTX) and Amarin (NASDAQ:AMRN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations, media sentiment and institutional ownership.

In the previous week, Seaport Therapeutics had 7 more articles in the media than Amarin. MarketBeat recorded 11 mentions for Seaport Therapeutics and 4 mentions for Amarin. Amarin's average media sentiment score of 1.10 beat Seaport Therapeutics' score of 0.10 indicating that Amarin is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Seaport Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	3 Very Negative mention(s)	Neutral
Amarin	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Seaport Therapeutics has a net margin of 0.00% compared to Amarin's net margin of -14.56%. Seaport Therapeutics' return on equity of 0.00% beat Amarin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seaport Therapeutics	N/A	N/A	N/A
Amarin	-14.56%	-0.20%	-0.14%

Seaport Therapeutics presently has a consensus target price of $38.57, indicating a potential upside of 112.51%. Amarin has a consensus target price of $13.00, indicating a potential upside of 8.06%. Given Seaport Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Seaport Therapeutics is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seaport Therapeutics	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.67
Amarin	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00

22.3% of Amarin shares are held by institutional investors. 4.2% of Amarin shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Amarin has higher revenue and earnings than Seaport Therapeutics. Amarin is trading at a lower price-to-earnings ratio than Seaport Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seaport Therapeutics	N/A	N/A	-$74.88M	-$12.12	N/A
Amarin	$213.65M	1.19	-$38.80M	-$0.99	N/A

Summary

Seaport Therapeutics beats Amarin on 8 of the 14 factors compared between the two stocks.

How does Amarin compare to Alto Neuroscience?

Alto Neuroscience (NYSE:ANRO) and Amarin (NASDAQ:AMRN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Alto Neuroscience has a beta of 1.31, indicating that its stock price is 31% more volatile than the broader market. Comparatively, Amarin has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market.

In the previous week, Amarin had 2 more articles in the media than Alto Neuroscience. MarketBeat recorded 4 mentions for Amarin and 2 mentions for Alto Neuroscience. Amarin's average media sentiment score of 1.10 beat Alto Neuroscience's score of 0.22 indicating that Amarin is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alto Neuroscience	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amarin	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

22.3% of Amarin shares are held by institutional investors. 11.3% of Alto Neuroscience shares are held by company insiders. Comparatively, 4.2% of Amarin shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Alto Neuroscience currently has a consensus price target of $37.25, indicating a potential upside of 52.66%. Amarin has a consensus price target of $13.00, indicating a potential upside of 8.06%. Given Alto Neuroscience's stronger consensus rating and higher possible upside, equities research analysts plainly believe Alto Neuroscience is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alto Neuroscience	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Amarin	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00

Amarin has higher revenue and earnings than Alto Neuroscience. Amarin is trading at a lower price-to-earnings ratio than Alto Neuroscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A
Amarin	$213.65M	1.19	-$38.80M	-$0.99	N/A

Alto Neuroscience has a net margin of 0.00% compared to Amarin's net margin of -14.56%. Amarin's return on equity of -0.20% beat Alto Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alto Neuroscience	N/A	-46.46%	-39.09%
Amarin	-14.56%	-0.20%	-0.14%

Summary

Amarin beats Alto Neuroscience on 9 of the 16 factors compared between the two stocks.

How does Amarin compare to Cybin?

Amarin (NASDAQ:AMRN) and Cybin (NASDAQ:HELP) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Amarin currently has a consensus target price of $13.00, suggesting a potential upside of 8.06%. Cybin has a consensus target price of $46.33, suggesting a potential upside of 292.66%. Given Cybin's stronger consensus rating and higher probable upside, analysts plainly believe Cybin is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00
Cybin	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00

22.3% of Amarin shares are owned by institutional investors. Comparatively, 17.9% of Cybin shares are owned by institutional investors. 4.2% of Amarin shares are owned by company insiders. Comparatively, 15.0% of Cybin shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Cybin had 1 more articles in the media than Amarin. MarketBeat recorded 5 mentions for Cybin and 4 mentions for Amarin. Amarin's average media sentiment score of 1.10 beat Cybin's score of 0.87 indicating that Amarin is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amarin	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cybin	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cybin has a net margin of 0.00% compared to Amarin's net margin of -14.56%. Amarin's return on equity of -0.20% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amarin	-14.56%	-0.20%	-0.14%
Cybin	N/A	-71.78%	-64.81%

Amarin has higher revenue and earnings than Cybin. Amarin is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$213.65M	1.19	-$38.80M	-$0.99	N/A
Cybin	N/A	N/A	-$148M	-$3.02	N/A

Amarin has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market. Comparatively, Cybin has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market.

Summary

Amarin beats Cybin on 9 of the 16 factors compared between the two stocks.

How does Amarin compare to Theravance Biopharma?

Amarin (NASDAQ:AMRN) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.

In the previous week, Amarin had 4 more articles in the media than Theravance Biopharma. MarketBeat recorded 4 mentions for Amarin and 0 mentions for Theravance Biopharma. Amarin's average media sentiment score of 1.10 beat Theravance Biopharma's score of 0.00 indicating that Amarin is being referred to more favorably in the media.

Company	Overall Sentiment
Amarin	Positive
Theravance Biopharma	Neutral

Amarin presently has a consensus price target of $13.00, suggesting a potential upside of 8.06%. Theravance Biopharma has a consensus price target of $19.40, suggesting a potential upside of 13.92%. Given Theravance Biopharma's higher possible upside, analysts clearly believe Theravance Biopharma is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00
Theravance Biopharma	0 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Theravance Biopharma has a net margin of 51.58% compared to Amarin's net margin of -14.56%. Amarin's return on equity of -0.20% beat Theravance Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amarin	-14.56%	-0.20%	-0.14%
Theravance Biopharma	51.58%	-0.77%	-0.46%

Amarin has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market. Comparatively, Theravance Biopharma has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market.

Theravance Biopharma has lower revenue, but higher earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$213.65M	1.19	-$38.80M	-$0.99	N/A
Theravance Biopharma	$104.31M	8.48	$105.89M	$1.01	16.86

22.3% of Amarin shares are owned by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are owned by institutional investors. 4.2% of Amarin shares are owned by insiders. Comparatively, 7.7% of Theravance Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Theravance Biopharma beats Amarin on 8 of the 15 factors compared between the two stocks.

Get Amarin News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AMRN vs. The Competition

Export

Metric	Amarin	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$254.11M	$12.40B	$7.25B	$13.30B
Dividend Yield	N/A	2.63%	2.52%	22.58%
P/E Ratio	-12.15	797.58	275.29	26.14
Price / Sales	1.19	751.21	582.85	87.84
Price / Cash	33.33	86.66	76.96	53.71
Price / Book	0.55	10.71	11.22	6.33
Net Income	-$38.80M	$2.84B	$3.50B	$382.15M
7 Day Performance	-2.59%	-0.94%	-0.89%	-1.40%
1 Month Performance	-12.83%	-3.67%	-4.02%	-3.35%
1 Year Performance	-34.01%	-3.97%	7.13%	1.49%

Amarin Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AMRN Amarin	1.4805 of 5 stars	$12.03 +0.3%	$13.00 +8.1%	-34.0%	$254.11M	$213.65M	N/A	80	Positive News
PCRX Pacira BioSciences	1.7611 of 5 stars	$25.05 -0.6%	$30.14 +20.3%	+62.5%	$1.00B	$746.16M	71.57	829	Trending News Analyst Forecast Insider Trade
SPTX Seaport Therapeutics	2.7833 of 5 stars	$18.50 +0.4%	$38.57 +108.5%	N/A	$986.03M	N/A	N/A	58	News Coverage Analyst Forecast
ANRO Alto Neuroscience	2.058 of 5 stars	$23.97 -3.3%	$37.25 +55.4%	+331.0%	$973.20M	N/A	N/A	68
HELP Cybin	4.1792 of 5 stars	$11.42 -2.4%	$46.33 +305.7%	N/A	$921.73M	N/A	N/A	100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AMRN) was last updated on 10/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amarin (AMRN) Competitors

AMRN vs. PCRX, SPTX, ANRO, HELP, and TBPH

How does Amarin compare to Pacira BioSciences?

Summary

How does Amarin compare to Seaport Therapeutics?

Summary

How does Amarin compare to Alto Neuroscience?

Summary

How does Amarin compare to Cybin?

Summary

How does Amarin compare to Theravance Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMRN vs. The Competition

Amarin Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Amarin (AMRN) Competitors

AMRN vs. PCRX, SPTX, ANRO, HELP, and TBPH

How does Amarin compare to Pacira BioSciences?

Is AMRN or PCRX more profitable?

Which has more volatility and risk, AMRN or PCRX?

Do analysts prefer AMRN or PCRX?

Does the media favor AMRN or PCRX?

Do institutionals & insiders have more ownership in AMRN or PCRX?

Which has preferable valuation and earnings, AMRN or PCRX?

Summary

How does Amarin compare to Seaport Therapeutics?

Does the media prefer SPTX or AMRN?

Is SPTX or AMRN more profitable?

Do analysts prefer SPTX or AMRN?

Do institutionals and insiders believe in SPTX or AMRN?

Which has higher earnings & valuation, SPTX or AMRN?

Summary

How does Amarin compare to Alto Neuroscience?

Which has more risk and volatility, ANRO or AMRN?

Does the media prefer ANRO or AMRN?

Do institutionals & insiders believe in ANRO or AMRN?

Do analysts prefer ANRO or AMRN?

Which has stronger valuation & earnings, ANRO or AMRN?

Is ANRO or AMRN more profitable?

Summary

How does Amarin compare to Cybin?

Do analysts recommend AMRN or HELP?

Do insiders & institutionals believe in AMRN or HELP?

Does the media favor AMRN or HELP?

Is AMRN or HELP more profitable?

Which has higher earnings & valuation, AMRN or HELP?

Which has more risk and volatility, AMRN or HELP?

Summary

How does Amarin compare to Theravance Biopharma?

Does the media prefer AMRN or TBPH?

Do analysts prefer AMRN or TBPH?

Is AMRN or TBPH more profitable?

Which has more risk & volatility, AMRN or TBPH?

Which has preferable valuation & earnings, AMRN or TBPH?

Do insiders & institutionals hold more shares of AMRN or TBPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMRN vs. The Competition

Amarin Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools